Compare TBPH & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | INMD |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 842.0M |
| IPO Year | 2013 | 2018 |
| Metric | TBPH | INMD |
|---|---|---|
| Price | $16.34 | $13.80 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $18.40 | $17.33 |
| AVG Volume (30 Days) | 282.6K | ★ 768.1K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $8.46 | $1.74 |
| Revenue Next Year | N/A | $3.26 |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.10 | $12.72 |
| 52 Week High | $21.03 | $16.74 |
| Indicator | TBPH | INMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 44.92 |
| Support Level | $16.14 | $13.27 |
| Resistance Level | $17.21 | $13.87 |
| Average True Range (ATR) | 0.38 | 0.32 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 29.31 | 47.03 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.